Breastfeeding: Avoid use while breastfeeding unless specifically advised by a healthcare provider
CagriSema combination profile When cagrilintide is combined with semaglutide, the weight loss results are substantially better, averaging 20.4% body weight reduction versus 11.8% with cagrilintide alone
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
Current studies dont suggest major differences in overall weight loss efficacy based solely on injection zonehowever, consistency in both dosage and schedule remains critical
#Ambulatory_Pharmacy #Ampulatory_Pharmacist #Clinical_Pharmacy #Diabetes To view or add a comment, sign in New review explores how the #Immunoproteasome contributes to #Diabetes and its associated complications, offering insights into novel #therapeutic strategies for diabetes management